To evaluate the efficacy of avatinib plus allogeneic hematopoietic stem cell transplantation(allo-HSCT)for the treatment of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia(AML)with KIT mutations. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.